Arvinas, Inc. (ARVN)

32.82 +0.39 (+1.20%) At close: 04:00PM EDT

Arvinas, Inc.

5 Science Park
395 Winchester Avenue
New Haven, CT 06511
United States
203 535 1456
https://www.arvinas.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 445

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. John G. Houston Ph.D.	Chairperson, CEO & President	1.14M	N/A	1960
Dr. Ian Taylor Ph.D.	Chief Scientific Officer	732.26k	N/A	1963
Ms. Angela M. Cacace Ph.D.	Senior Vice President of Neuroscience & Platform Biology	N/A	N/A	1968
Mr. John P. Northcott	Chief Commercial Officer	N/A	N/A	1978
Ms. Lisa Sinclair	Senior Vice President of Corporate Operations	N/A	N/A	N/A
Mr. Paul McInulty	Senior Vice President of Regulatory Affairs	N/A	N/A	N/A
Mr. Alexander A. Santini	Senior Vice President of Global & U.S. Market Access	N/A	N/A	1959
Ms. Kelly Page	Senior VP & Global Head of Oncology Strategy and Program Leadership	N/A	N/A	N/A
Dr. Eric Masson Pharm.D.	Senior Vice President of Early Clinical Development	N/A	N/A	N/A
Dr. Janet Wang Ph.D.	VP & Head of Translational Sciences, Oncology	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Corporate Governance

Arvinas, Inc.’s ISS Governance QualityScore as of May 1, 2024 is 7. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 9; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.